
    
      This is a multicenter, open-label, Phase 1 a/b dose escalation study of safety,
      pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to
      determine the MTD or recommended dose in patients with relapsed or refractory Acute Myeloid
      Leukemia (except APML), secondary AML, or therapy-related AML whose disease has relapsed, is
      refractory or who are ineligible for or intolerant of intensive chemotherapy or
      transplantation. This is to be followed by a cohort expansion phase at the candidate
      recommended Phase 2 dose.
    
  